Background: The nonvitamin K antagonist oral anticoagulants pivotal clinical trials for stroke
prevention in atrial fibrillation have important differences in trial designs and baseline patient …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background Edoxaban recently proved non-inferior to warfarin for prevention of
thromboembolism in patients with non-valvular atrial fibrillation (AF). We conducted an …

Background and aim Current observational studies have compared the effectiveness and
safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still …

Background The aim of the study was to compare the real-world effectiveness and safety in
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …

The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for stroke
prevention in many patients with nonvalvular atrial fibrillation. Edoxaban, an oral factor Xa …

Background Much direct evidence has proved that the novel oral anticoagulants (NOACs)
are noninferior or superior to warfarin for stroke prevention in patients with nonvalvular atrial …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Purpose We aimed to determine the safety of direct oral anticoagulants (DOACs) for stroke
prevention and treatment in patients with atrial fibrillation (AF). Methods A systematic search …

Aim Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor
approved for the prevention of stroke and systemic embolism in adult patients with atrial …